CSSD-0511-BMS2600000001-1 | DIRECT AWARD - RAZORMETRICS RXEDGE TECH PLATFORM

The contract is a direct award sole-source procurement issued by the West Virginia Department of Administration, Purchasing Division, for the RazorMetrics RxEdge Technology Platform, a cloud-based software-as-a-service solution designed to optimize pharmacy benefit management through automated medication switch recommendations, deprescribing support, and biosimilar interchange tools. The platform integrates seamlessly into existing electronic health record systems without requiring new software, portals, or logins, and operates using pharmacy claims data, formulary updates, and switch override instructions provided by the state. The contract’s estimated value ranges from $2.36 million to $9.45 million, depending on whether all three optional one-year renewals are exercised, with pricing set at a fixed $0.50 per member per month based on an estimated enrollment of 393,610 Medicaid members. Payment is made monthly, beginning on the mutually agreed-upon kick-off date, with invoicing processed through the Bureau for Medical Services in Charleston, West Virginia. The procurement is justified under West Virginia Code § 5A-3-10c due to the proprietary and uniquely non-replicable nature of the RazorMetrics platform, with no competitive bidding conducted. A critical performance requirement is a guaranteed 2:1 return on investment within the first 12 months after go-live, with financial penalties if savings targets are not met. The vendor is responsible for delivering automated prescriber alerts, real-time tracking of switches, and monthly analytics, all contingent upon timely submission of enrollment data, pharmacy claims, and formulary changes from the state. Implementation must be completed within 90 days of data receipt, with initial switches delivered 60 days after verification. The contract term is one year from kickoff, renewable up to three additional years by mutual agreement. The state does not provide rebate agreements or SSDC supplemental drug data, and the platform must rely on existing claim-level cost benchmarks. Performance metrics, data quality adherence, and savings validation are governed by a jointly defined methodology, with no formal inspection or acceptance criteria specified beyond these performance thresholds. The primary point of contact for procurement is Crystal G. Hustead, with shared functional oversight by Gary Knight and Kristen Boustany across pharmacy, IT, and finance functions.